Clinical Trial Update: Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) [Phase 2]

View source ↗

Summary

Phase 2 trial of ACE-083 in facioscapulohumeral muscular dystrophy was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy

Drugs mentioned

• ACE-083

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Facioscapulohumeral Muscular Dystrophy | Phase 2 | Status: TERMINATED | Results posted: 2021-04-22